HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy

Frontiers in Immunology - Switzerland
doi 10.3389/fimmu.2018.02605
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

P53 Codon 72 Polymorphism Predicts the Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2005English

Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer

Journal of Medical – Clinical Research & Reviews
2019English

MRP1 but Not MDR1 Is Associated With Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

Disease Markers
BiochemistryMedicineClinical BiochemistryMolecular BiologyGenetics
2013English

Neoadjuvant Chemotherapy in Breast Cancer

English

Neoadjuvant Chemotherapy: Role in Breast Cancer

2013English

Neutrophil–lymphocyte Ratio Predicts Response to Chemotherapy in Triple-Negative Breast Cancer

Current Oncology
Oncology
2018English

Comedications Influence Immune Infiltration and Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer

OncoImmunology
OncologyAllergyImmunology
2019English

Local-Regional Control According to Surrogate Markers of Breast Cancer Subtypes and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast Conserving Therapy

Breast Cancer Research
Cancer ResearchOncology
2012English

Correlation of Post-Neoadjuvant Chemotherapy Response on MRI With Final Histology in Breast Cancer Patients

Breast Cancer Research
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy